This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 ...

Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (IOVA 5.27%) shares closed Thursday more than 5% higher in price.

Investors are fortunate to have access to a universe of stocks that they can buy or sell at any given time. Sometimes, however, limiting your options can be a powerful exercise.

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in ...

It hasn't been a great year for Iovance Biotherapeutics (IOVA -1.40%), an innovative mid-cap biotech company. The drugmaker's shares have significantly lagged the market -- advancing only about 5% so ...

It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story.

The biotech industry has been described as the Wild West of the stock market. Although some companies manage to develop and commercialize a life-changing therapeutic, countless more start-ups inevitab...

As the rising star of cell therapy biotechs, Iovance Biotherapeutics (IOVA 3.76%) is a hot stock that's capturing a lot of attention, and for good reason. Iovance's one-of-a-kind medicine is already s...

2 Innovative Stocks That Could Deliver Outsize Returns

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows st...

Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.

Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.